Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium
Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium
据报道，Aileron Therapeutics将在第22届肺纤维化研讨会上发布LTI-03用于特发性肺纤维化的第10亿期试验数据
- First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect
- Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term
- 对正在进行的第10亿临床试验中Cohort 1中低剂量LTI-03（2.5 mg 买盘）的先前公布数据进行首次科学表达，肺纤维化患者八项生物标志物中有七项呈现积极趋势，暗示潜在疗效
- 最近完成了Cohort 2的高剂量LTI-03（5 mg 买盘）的入组评估，预计在短期内公布上线数据
资讯热榜
更新时间